Literature DB >> 15183949

Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.

Denis Chautard1, Isabelle Dalifard, Agnes Chassevent, Serge Guyetant, Alain Daver, Bruno Vielle, Jean Yves Soret.   

Abstract

OBJECTIVES: To examine whether urokinase-type plasminogen activator (uPA) and type 1 plasminogen inhibitor (PAI-1), DNA ploidy, and S-phase fraction (SPF) add supplementary prognostic information relative to stage and Fuhrman's grade in renal cell carcinoma.
METHODS: A total of 100 patients with primary renal adenocarcinoma treated by nephrectomy were followed up for a median of 42 months. Of the 100 patients, 78 with Stage M0N0-Nx tumors were studied by multivariate analysis. The study population was dichotomized on the basis of the median cytosolic uPA and PAI-1 concentrations (30 pg/mg protein and 12.7 ng/mg protein, respectively). DNA content was measured by flow cytometry (FCM) on multiple tumor samples from each patient. DNA aneuploidy was observed in 67% of cases. The SPF was calculated for aneuploid samples.
RESULTS: An FCM classification based on a combination of DNA content and SPF was obtained. High-risk patients were those with aneuploid tumors and high SPF values (greater than 1.7%) and included 23% of patients with M0N0-Nx tumors. Cytosolic uPA and PAI-1 levels were not predictive of metastasis. The stage, grade, SPF, and FCM classification were statistically significant prognostic factors in the univariate analysis, in both the overall population and the M0N0-Nx subgroup. In multivariate analysis, tumor grade and the FCM classification were the only independent predictors of disease-free survival (P = 0.018 and P = 0.046, respectively).
CONCLUSIONS: We defined a group of M0N0-Nx patients with aneuploid tumors and high SPF values who are at a high risk of metastasis and who may benefit from closer long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183949     DOI: 10.1016/j.urology.2004.01.013

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.

Authors:  Naoko Honma; Takamitsu Inoue; Norihiko Tsuchiya; Atsushi Koizumi; Ryohei Yamamoto; Taketoshi Nara; Sohei Kanda; Mingguo Huang; Kazuyuki Numakura; Mitsuru Saito; Shintaro Narita; Shigeru Satoh; Tomonori Habuchi
Journal:  Health Sci Rep       Date:  2020-10-15

Review 2.  Genomics of renal cell cancer-- does it provide breakthrough?

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2006-03-23       Impact factor: 3.201

3.  Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.

Authors:  Dragomir P Zubac; Tore Wentzel-Larsen; Tomas Seidal; Leif Bostad
Journal:  BMC Urol       Date:  2010-12-03       Impact factor: 2.264

4.  Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.

Authors:  Susanne Fuessel; Kati Erdmann; Helge Taubert; Andrea Lohse-Fischer; Stefan Zastrow; Matthias Meinhardt; Karen Bluemke; Lorenz Hofbauer; Paolo Fornara; Bernd Wullich; Gustavo Baretton; Viktor Magdolen; Manfred P Wirth; Matthias Kotzsch
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

5.  A non-diploid DNA status is linked to poor prognosis in renal cell cancer.

Authors:  Franziska Büscheck; Christoph Fraune; Martina Kluth; Maximilian Lennartz; Ronald Simon; Claudia Hube-Magg; Christian Morlock; Silvano Barbieri; Carolin Wahl; Christian Eichelberg; Christina Möller-Koop; Doris Höflmayer; Corinna Wittmer; Waldemar Wilczak; Guido Sauter; Margit Fisch; Till Eichenauer; Michael Rink
Journal:  World J Urol       Date:  2020-05-02       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.